“We have strong conviction in the potential for STAR-0215 to be the first-choice preventative therapy for HAE,” said Jill C. Milne, Chief Executive Officer at Astria Therapeutics. “Our final data from the Phase 1a trial demonstrate that STAR-0215, in addition to having a trusted modality and proven mechanism, has a favorable safety profile with low risk of injection site pain and has the potential to achieve rapid and durable protection against HAE attacks. We are looking forward to sharing initial proof-of-concept data in HAE patients this quarter and believe they could support dosing as infrequently as every six months. STAR-0310 for atopic dermatitis also remains on track for expected preclinical results later this year and an IND submission by year-end.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATXS:
- Astria Therapeutics Announces Offering to Fund Future Operations
- Astria Therapeutics Secures Funds for R&D Through Stock Sale
- Astria Therapeutics Completes $50M Common Stock Sale
- Astria Therapeutics 10.34M share Secondary priced at $12.09
- 3 Best Stocks to Buy Now, 1/23/2024, According to Top Analysts
